14th European Congress of Clinical Microbiology and Infectious ...

Poster Sessions Sunday, May 2, 2004
P533 Anti-pneumocystis activity of iclaprim, a
reliable therapeutic alternative against
Pneumocystis pneumonia
E.M. Aliouat, E. Dei-Cas, N. Gantois, K. Islam,
S. Hawser (Lille, F; Munchenstein, CH)
P534 In vitro plasma fibrin clot models versus in
vivo models of experimental endocarditis:
case study for diaminopyrimidine antibiotics
iclaprim and trimethoprim/sulfamethoxazole
J.M. Entenza, M. Giddey, J. Vouillamoz,
S. Hawser, P. Moreillon (Lausanne, Basle, CH)
P535 Antimicrobial activity of the novel
cephalosporin LB11058 tested against
pathogens commonly associated with
bacterial meningitis
H. Sader, D. Johnson, D.J. Biedenbach, R. Jones
(North Liberty, USA)
P536 Gram-negative bacteria producing
characterised beta-lactamases: in vitro
activities of BAL9141 and comparators
M. Kresken, M. Heep, I. Wiegand
(Bonn, D; Basel, CH)
P537 MIC determination of the anti-pneumococcal
activity of BAL 9141 compared to other agents
P. Appelbaum, D. Hoellman, M. Jacobs
(Hershey, Cleveland, USA)
P538 Efficacy and safety of pharmacokinetically
enhanced amoxicillin/clavulanate 2000/125 mg
in adult patients with acute bacterial sinusitis
in Hungary
L. Tamas, P. Kovacs, G. Horvai, M. Twynholm
(Budapest, HUN; Harlow, UK)
P539 An in vitro evaluation of the antimicrobial
activity of a novel fluoroquinolone
M.J. Robbins, D. De Rubeis, C. Dencer,
L. Williams, M. Harrison, A. Bryskier,
D. Felmingham (London, UK; Romainville, F)
P540 Intracellular penetration and activity of
cethromycin against Legionella pneumophila
in a monocytic cell line (Mono Mac 6)
I. García, S. Ballesta, E.J. Perea, Á. Pascual
(Seville, E)
P541 Phase 2 trial comparing four regimens of
oritavancin vs comparator in the treatment
of patients with S. aureus bacteraemia
J.S. Loutit, W. O'Riordan, J. San Juan, J. Mensa,
R. Hanning, S. Huang, S. Porter
(Brisbane, Chula Vista, USA; Buenos Aires, AR;
Barcelona, E)
P542 Linezolid in the treatment of skin and soft
tissue infections caused by methicillinresistant
Staphylococcus aureus
N. Alikadic, D. Smrke (Ljubljana, SI)
P543 Linezolid tolerance among multiresistant
nasopharyngeal isolates of Streptococcus
pneumoniae
A. Malm, I. Korona-Glowniak, A. Kalasiewicz
(Lublin, PL)
P544 New penams (6-APA) and cephems (7-ACA)
with bulky T-shaped side-chains: synthesis
and antibiotic activities
L. Efron, T. Happaerts, E. Sonveaux, H. Chanteux,
Y. Glupczynski, C. Behrin, F. Van Bambeke,
P. Tulkens (Brussels, B)
P545 In vitro and in vivo activities of novel
compounds active against multiresistant
strains of Mycobacterium tuberculosis
U. Möllmann, L.P. Martinova, S. Rüsch-Gerdes,
V.A. Makarov (Jena, D; Moscow, RUS; Borstel, D)
P546 Basidiomycete metabolites attenuate
virulence properties of Candida albicans in
vitro
L. Pleyer, S. Ressler, A. Berg, M.P. Dierich,
R. Würzner (Innsbruck, A; Jena, D)
P547 Search and assessment of novel substances
active against Epstein-Barr virus
S. Zagorodnya, N. Dyachenko, N. Nesterova,
V. Atamaniuk, A. Novik, S. Rybalko, G. Baranova
(Kiev, UKR)
P548 A phase 2 study of the toxin binding polymer
tolevamer in patients with C. difficile
associated diarrhoea
D. Davidson, J. Peppe, T. Louie –
The Tolevamer Working Group
P549 A novel antimicrobial system to treat
methicillin-resistant and glycopeptideresistant
staphylococci
B. Cookson, M. Embleton, S. Nair, M. Wilson
(London, UK)
P550 Novel “ethiological” therapies for AIDSrelated
Kaposi's sarcoma, and possible
laboratory monitoring
R. Manfredi, L. Calza, F. Chiodo (Bologna, I)
P551 A novel antiviral based on oral antibodies:
clinical benefits in paediatric upper
respiratory infections
A.V. Martyushev-Poklad, V.F. Uchaikin,
M.P. Kotelnikova, J.L. Dugina, O.I. Epstein,
S.A. Sergeeva (Moscow, RUS)
www.escmid.org/eccmid2004
page 71